Why the study?
Although REDUCE-IT demonstrated the benefits of icosapent ethyl on ischemic events, its generalizability to a contemporary CABG population is not known.
What proportion of post-CABG patients on statin therapy are eligible for icosapent ethyl treatment?
What proportion of post-CABG patients on statin therapy are eligible for icosapent ethyl treatment?
A significant proportion (22-34%) of contemporary post-CABG patients on statin therapy meet criteria for icosapent ethyl, supporting its potential role as an adjunct secondary prevention therapy.
Answers are grounded in this paper and cite their sources.
Clinicians can now identify post-CABG IPE candidates; extends REDUCE-IT generalizability to contemporary statin-treated surgical patients.
PURPOSE OF REVIEW: Following coronary artery bypass grafting (CABG), there remains persistent risk of ischemic events despite secondary prevention strategies, including low-density lipoprotein cholesterol lowering. Although REDUCE-IT recently demonstrated the benefits of icosapent ethyl (IPE) on reducing ischemic events in a broad population of primary and secondary prevention patients, its generalizability to a contemporary CABG population is not known. This article aims to ascertain the proportion of patients with a history of CABG that would be eligible for IPE treatment. RECENT FINDINGS: A review of recent literature highlights the presence of residual ischemic following CABG. Using the Québec Heart Database, a repository of contemporary Canadian cardiac patient information, was searched between 1 January 2006 and 31 December 2016, to ascertain generalizability of IPE. SUMMARY: In a large (N = 12 641), contemporary, Canadian cohort of patients with a history of CABG and currently on statin therapy, 21.9, 33.6 and 26.4% would be eligible for IPE, according to REDUCE-IT, Health Canada, and Food and Drug Administration criteria, respectively. These analyses would support IPE as an adjunct to secondary prevention therapies post-CABG.
No takes yet. Share an insight, caveat, or question.
Kosmopoulos et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: